Overview

A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This will be a phase I, single center, randomized, vehicle-controlled, blinded study comparing two dosage strengths of CRx-197 cream, nortriptyline, an active comparator (0.1% mometasone) and placebo (the active ingredient free vehicle cream of CRx-197)in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Zalicus
Treatments:
Loratadine
Mometasone Furoate
Nortriptyline